Provided by Tiger Trade Technology Pte. Ltd.

INmune Bio Inc

1.12
-0.0800-6.67%
Post-market: 1.150.0300+2.68%18:37 EDT
Volume:375.67K
Turnover:433.56K
Market Cap:29.78M
PE:-0.53
High:1.20
Open:1.20
Low:1.12
Close:1.20
52wk High:11.64
52wk Low:1.12
Shares:26.59M
Float Shares:20.18M
Volume Ratio:0.50
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1078
EPS(LYR):-2.1100
ROE:-155.77%
ROA:-50.59%
PB:1.17
PE(LYR):-0.53

Loading ...

INmune Bio Inc - Company Terminates Sales Agreement Effective December 19, 2025 - SEC Filing

THOMSON REUTERS
·
Dec 11, 2025

INmune Bio Inc - on Dec 5, Enters Amendment No. 5 to Rights Agreement - SEC Filing

THOMSON REUTERS
·
Dec 09, 2025

INmune Bio Reports Phase 2 Trial Data Showing XPro1595 Slows Neurodegeneration in Early Alzheimer’s Disease

Reuters
·
Dec 06, 2025

INmune Bio Highlights CORDStrom Platform’s Promise in Stromal Cell Therapy Research

Reuters
·
Dec 05, 2025

INmune Bio Inc. Updates Executive Compensation Agreements

Reuters
·
Dec 04, 2025

INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease

Reuters
·
Dec 01, 2025

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

GlobeNewswire
·
Nov 18, 2025

INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO

Reuters
·
Oct 31, 2025

INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate

Benzinga
·
Oct 31, 2025

INmune Bio Q3 Basic EPS USD -0.24

THOMSON REUTERS
·
Oct 31, 2025

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

GlobeNewswire
·
Oct 31, 2025

INmune Bio Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Oct 29, 2025

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

GlobeNewswire
·
Oct 23, 2025

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

GlobeNewswire
·
Oct 14, 2025

INmune Bio Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Oct 04, 2025

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

TIPRANKS
·
Sep 29, 2025

INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation

Reuters
·
Sep 29, 2025

INmune Bio Announces Submission of Phase 2 Mindful Trial Results in Alzheimer’s Disease to Npj Dementia, a Nature Portfolio Journal

THOMSON REUTERS
·
Sep 29, 2025